Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005862
Status:
COMPLETED
Last Update Posted:
2013-02-11
First Post:
2000-06-02
Brief Title:
SU5416 in Treating Patients With Advanced Metastatic or Recurrent Soft Tissue Sarcomas
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase II Trial of SU5416 NSC 696819 in Previously Treated Patients With Advanced Metastatic andor Locally Recurrent Soft Tissue Sarcomas
Status:
COMPLETED
Status Verified Date:
2002-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced metastatic or recurrent soft tissue sarcomas SU5416 may stop the growth of soft tissue sarcomas by stopping blood flow to the tumor
Detailed Description:
OBJECTIVES
I Determine the response rate response duration and overall survival in patients with advanced metastatic or recurrent soft tissue sarcoma or gastrointestinal stromal tumor when treated with SU5416
II Determine the safety of SU5416 in these patients
OUTLINE This is a multicenter study
Patients receive SU5416 IV twice weekly for 4 weeks Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity
Patients are followed monthly for 3 months and then every 3 months for 1 year
I Determine the response rate response duration and overall survival in patients with advanced metastatic or recurrent soft tissue sarcoma or gastrointestinal stromal tumor when treated with SU5416
II Determine the safety of SU5416 in these patients
OUTLINE This is a multicenter study
Patients receive SU5416 IV twice weekly for 4 weeks Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity
Patients are followed monthly for 3 months and then every 3 months for 1 year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-330 | None | None | None |
| DFCI-00002 | None | None | None |